Generic drugs: What are the problems and how can they be explained?;Les médicaments génériques: Quels sont les problèmes et d'où viennent-ils?

Medecine et Hygiene

Volumn 61, Issue 2434, 2003, Pages 879-884

  Baumann, Pierre ^b   Kahn, J M ^a  

^a Hlthcare and Project Management HPM   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIDEPRESSANT AGENT; CLOZAPINE; DUOCID; FLUOXETINE; GENERIC DRUG; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; VERAPAMIL;

BIOEQUIVALENCE; CYSTIC FIBROSIS; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MECHANISM; DRUG PROGRAM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; NEUROPSYCHIATRY; PHARMACODYNAMICS; PRESCRIPTION; REVIEW; STATISTICAL DISTRIBUTION; STOMACH PROTECTION; TREATMENT FAILURE;

EID: 0038331662     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Meredith PA. Generic drugs. Therapeutic equivalence. Drug Safety 1996; 15: 233-42.
2. CDER. What are generic drugs? In: www.fda.gov/cder/ogd/index.htm ed; 2002.
3. Colaizzi JL, Lowenthal DT. Critical therapeutic categories: A contraindication to generic substitution? Clin Ther 1986; 8: 370-9.
4. OICM. Instructions de l'OICM pour la présentation des demandes d'enregistrement de préparations génériques à un seul principe actif destinées à l'usage humain. Berne, Suisse: Swissmedic; 1991.
5. Tucker GT. Chiral switches. Lancet 2000; 355: 1085-7.
6. Baumann P, Zullino DF, Eap CB. Enantiomers' potential in psychopharmacology - a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12: 433-44.
7. Mühlebach S, Beutler M. Les produits génériques. Equivalents thérapeutiques à prix réduit? Journal suisse de pharmacie 1999; 4: 108-10.
8. Barone JA. Comparative potency and dissolution performance of internationally available piroxicam products. Pharmacoeconomics 1992; 1 (Suppl.): 49-52.
9. Dong BJ, Brown CH. Hypothyroidism resulting from generic levothyroxine failure. J Am Board Fam Pract 1991; 4: 167-70.
10. Wildfeuer A, Zimmermann T, Eibel G, et al. Relative bioavailability of sultamicillin in healthy volunteers following administration of two tablet formulations. J Int Med Res 1992; 20 (Suppl. 1): 4A-11A.
11. Diamond BI, Albrecht JW. Medical and psychiatric implications of generic drugs. Psychopathology 1987; 20 (Suppl. 1): 92-8.
12. Dubovsky SL. Severe nortriptyline intoxication due to change from a generic to a trade preparation. J Nerv Ment Dis 1987; 175: 115-7.
13. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. JAMA 1990; 263: 2459-61.
14. Mindel JS. Bioavailability and generic prescribing. Surv Ophthalmol 1976; 21: 262-75.
15. Petersen KU. Original brands and generic preparations. Med Klin 2000; 95: 26-30.
16. Waldman SA, Morganroth J. Effects of food on the bioequivalence of different verapamil sustained-release formulations. J Clin Pharmacol 1995; 35: 163-9.
17. Joshi MV, Gokhale PC, Pohujani SM, et al. Bioinequivalence of marketed diltiazem preparations. Eur J Clin Pharmacol 1990; 39: 189-90.
18. Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 1995; 15: 433-40.
19. Bums M. Management of narrow therapeutic index drugs. J Thromb Thrombolysis 1999; 7: 137-43.
20. Carter BL, Noyes MA, Demmler RW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy 1993; 13: 359-68.
21. Guimont S, Landriault H, Klischer K, et al. Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. Biopharm Drug Dispos 1993; 14: 767-78.
22. Schnur W. Potential hazards of generic antidepressants in the elderly. Am Family Physician 1995; 51: 48.
23. Ostroff RB, Docherty JP. Tricyclics, bioequivalence, and clinical response. Am J Psychiatry 1978; 135: 1560-1.
24. Bakish D. A double-blind, crossover study comparing generic and brand Fluoxetine in the treatment of major depressive disorder. Int J Neuropsychopharmacol 2000; 3 (Suppl. 1): 234.
25. Compendium suisse des médicaments 2002: Documed AG; 2002.
26. Albrecht J, Adler RH. Therapeutic inadequacy in spite of bioequivalency on replacing Fluctine with Fluocim. Swiss Med Wkly 2001; 131: 84.
27. Hovaguimian T. Génériques et obsessions ou obsession du générique. A propos d'un cas de rechute d'un trouble obsessionnel compulsif lors d'une substitution de la fluoxétine par un générique. Med Hyg 1998; 56: 2085-8.
28. Hofmann E. Rapports de cas de patientes qui ont développé une allergie cutanée sous antidépresseur générique, Dübendorf, 2000.
29. Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001; 3: 281-4.
30. Lesser RP, Krauss G. Buy some today. Can generics be safely substituted for brand-name drugs? Neurology 2001; 57: 571-3.
31. Voirol P, Eap CB, Baumann P. Monitoring thérapeutique des psychotropes et tests pharmacogénétiques en psychiatrie. Rev Med Suisse romande 2000; 120: 99-104.